LNCaP prostate cancer cells with autocrine interleukin-6 expression are resistant to IL-6-induced neuroendocrine differentiation due to increased expression of suppressors of cytokine signaling

Prostate

Volumn 72, Issue 12, 2012, Pages 1306-1316

  Ge, Dongxia ^a   Gao, Allen C ^b   Zhang, Qiuyang ^a   Liu, Sen ^a   Xue, Yun ^a   You, Zongbing ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

IL 6; neuroendocrine; prostate cancer

Indexed keywords

CYTOKINE INDUCIBLE SH2 PROTEIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE 2; PROTEIN KINASE TYK2; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 6; SUPPRESSOR OF CYTOKINE SIGNALING 7; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CELL STRAIN LNCAP; CONTROLLED STUDY; CYTOKINE RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AUTOCRINE COMMUNICATION; CELL DIFFERENTIATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; JANUS KINASE 2; MALE; NEUROENDOCRINE CELLS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UP-REGULATION;

EID: 84864283846     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22479     Document Type: Article

References (73)

1. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA,. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. Jama 1991; 265 (5): 618-621.
2. Roudier MP, True LD, Higano CS, Vesselle H, Ellis W, Lange P, Vessella RL,. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003; 34 (7): 646-653. (Pubitemid 36875509)
3. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML,. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52 (24): 6940-6944. (Pubitemid 23006303)
4. July LV, Akbari M, Zellweger T, Jones EC, Goldenberg SL, Gleave ME,. Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy. Prostate 2002; 50 (3): 179-188. (Pubitemid 34137445)
5. Gleave M, Jansen B,. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann N Y Acad Sci 2003; 1002: 95-104. (Pubitemid 38253334)
6. Abrahamsson PA,. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6 (4): 503-519.
7. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP,. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9 (4): 401-406.
8. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP,. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57 (2): 314-319. (Pubitemid 27036612)
9. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39. (Pubitemid 38524696)
10. Newmark JR, Hardy DO, Tonb DC, Carter BS, Epstein JI, Isaacs WB, Brown TR, Barrack ER,. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89 (14): 6319-6323.
11. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP,. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332 (21): 1393-1398.
12. Mohler JL, Gregory CW, Ford OH 3rd, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS,. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10 (2): 440-448. (Pubitemid 38173980)
13. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP,. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66 (5): 2815-2825.
14. Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J,. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res 2009; 69 (1): 16-22.
15. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H,. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994; 54 (20): 5474-5478.
16. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, Harris AL, Horne CH, Neal DE,. p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992; 147 (2): 496-499.
17. Craft N, Shostak Y, Carey M, Sawyers CL,. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999; 5 (3): 280-285. (Pubitemid 29124362)
18. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, Marcelli M,. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res 2004; 64 (19): 7156-7168. (Pubitemid 39331031)
19. Debes JD, Schmidt LJ, Huang H, Tindall DJ,. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 2002; 62 (20): 5632-5636. (Pubitemid 35204712)
20. Abrahamsson PA,. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39 (2): 135-148.
21. di Sant' Agnese PA,. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992; 70 (1 Suppl): 254-268.
22. Vashchenko N, Abrahamsson PA,. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005; 47 (2): 147-155. (Pubitemid 40126970)
23. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE, Trepel JB,. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994; 91 (12): 5330-5334. (Pubitemid 24174320)
24. Bonkhoff H, Stein U, Remberger K,. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995; 26 (2): 167-170.
25. Bonkhoff H, Wernert N, Dhom G, Remberger K,. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991; 19 (2): 91-98.
26. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA,. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004; 59 (3): 328-336. (Pubitemid 38509766)
27. Levine L, Lucci JA 3rd, Pazdrak B, Cheng JZ, Guo YS, Townsend CM Jr, Hellmich MR,. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003; 63 (13): 3495-3502. (Pubitemid 36793027)
28. Iwamura M, di Sant'Agnese PA, Wu G, Benning CM, Cockett AT, Deftos LJ, Abrahamsson PA,. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993; 53 (8): 1724-1726. (Pubitemid 23127091)
29. Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ,. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004; 64 (15): 5489-5495. (Pubitemid 39006573)
30. Di Sant'Agnese PA, Cockett AT,. The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 1994; 152 (5 Pt 2): 1927-1931. (Pubitemid 24322661)
31. di Sant'Agnese PA, de Mesy Jensen KL,. Neuroendocrine differentiation in prostatic carcinoma. Hum Pathol 1987; 18 (8): 849-856. (Pubitemid 18049858)
32. Bonkhoff H, Stein U, Remberger K,. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: Simultaneous demonstration of cell-specific epithelial markers. Hum Pathol 1994; 25 (1): 42-46. (Pubitemid 24051823)
33. Abrahamsson PA, di Sant'Agnese PA,. Neuroendocrine cells in the human prostate gland. J Androl 1993; 14 (5): 307-309. (Pubitemid 23320869)
34. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjolnerod OK, Waldum HL,. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30 (1): 1-6. (Pubitemid 27053534)
35. Ismail AH, Landry F, Aprikian AG, Chevalier S,. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate 2002; 51 (2): 117-125.
36. Sciarra A, Di Silverio F,. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology 2004; 63 (3): 523-527.
37. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N,. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45 (5): 586-592 discussion 592. (Pubitemid 38481685)
38. Huss WJ, Gregory CW, Smith GJ,. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence. Prostate 2004; 60 (2): 91-97. (Pubitemid 38758574)
39. Cox ME, Deeble PD, Lakhani S, Parsons SJ,. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999; 59 (15): 3821-3830. (Pubitemid 29381892)
40. Deeble PD, Murphy DJ, Parsons SJ, Cox ME,. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001; 21 (24): 8471-8482. (Pubitemid 33108606)
41. Kim J, Adam RM, Freeman MR,. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation. Cancer Res 2002; 62 (5): 1549-1554. (Pubitemid 34407821)
42. Cox ME, Deeble PD, Bissonette EA, Parsons SJ,. Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 2000; 275 (18): 13812-13818. (Pubitemid 30257454)
43. Juarranz MG, Bolanos O, Gutierrez-Canas I, Lerner EA, Robberecht P, Carmena MJ, Prieto JC, Rodriguez-Henche N,. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors. Cell Signal 2001; 13 (12): 887-894. (Pubitemid 33139790)
44. Spiotto MT, Chung TD,. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000; 42 (3): 186-195. (Pubitemid 30080417)
45. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, deVere White RW,. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004; 60 (3): 257-271. (Pubitemid 38971837)
46. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R,. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162 (5): 1800-1805. (Pubitemid 29474732)
47. Qiu Y, Robinson D, Pretlow TG, Kung HJ,. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998; 95 (7): 3644-3649.
48. Adam RM, Kim J, Lin J, Orsola A, Zhuang L, Rice DC, Freeman MR,. Heparin-binding epidermal growth factor-like growth factor stimulates androgen-independent prostate tumor growth and antagonizes androgen receptor function. Endocrinology 2002; 143 (12): 4599-4608. (Pubitemid 35397601)
49. Wang Q, Horiatis D, Pinski J,. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 2004; 111 (4): 508-513. (Pubitemid 39045316)
50. Michalaki V, Syrigos K, Charles P, Waxman J,. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90 (12): 2312-2316. (Pubitemid 38961893)
51. Corcoran NM, Costello AJ,. Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91 (6): 545-553. (Pubitemid 36570580)
52. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC,. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161 (1): 182-187. (Pubitemid 29422316)
53. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP,. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999; 41 (2): 127-133. (Pubitemid 29446967)
54. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M,. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000; 6 (7): 2702-2706. (Pubitemid 30482107)
55. Culig Z, Puhr M,. Interleukin-6: A multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2011. In Press; PMID: 21664423; Epub ahead of print, doi:10.1016/j.mce.2011.05.033.
56. Giri D, Ozen M, Ittmann M,. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001; 159 (6): 2159-2165. (Pubitemid 33104270)
57. Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, Jou YS, Shih HM, Kung HJ, Chen RH,. Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation. Mol Cell Biol 2000; 20 (6): 2043-2054. (Pubitemid 30123820)
58. Grossmann ME, Huang H, Tindall DJ,. Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93 (22): 1687-1697. (Pubitemid 33130257)
59. Kim J, Adam RM, Solomon KR, Freeman MR,. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 2004; 145 (2): 613-619. (Pubitemid 38183803)
60. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC,. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003; 300 (5628): 2101-2104. (Pubitemid 36760138)
61. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K, Taga T, Kishimoto T,. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993; 260 (5115): 1808-1810. (Pubitemid 23244207)
62. Benigni F, Fantuzzi G, Sacco S, Sironi M, Pozzi P, Dinarello CA, Sipe JD, Poli V, Cappelletti M, Paonessa G, Pennica D, Panayotatos N, Ghezzi P,. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 1996; 87 (5): 1851-1854.
63. Ihle JN,. Cytokine receptor signalling. Nature 1995; 377 (6550): 591-594.
64. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L,. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334 (Pt 2): 297-314. (Pubitemid 28448572)
65. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW,. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999; 38 (3): 199-207. (Pubitemid 29054936)
66. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC,. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000; 42 (3): 239-242. (Pubitemid 30080423)
67. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC,. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9 (1): 370-376. (Pubitemid 36109754)
68. Nicholson SE, Hilton DJ,. The SOCS proteins: A new family of negative regulators of signal transduction. J Leukoc Biol 1998; 63 (6): 665-668. (Pubitemid 28274826)
69. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, Matsumoto A, Tanimura S, Ohtsubo M, Misawa H, Miyazaki T, Leonor N, Taniguchi T, Fujita T, Kanakura Y, Komiya S, Yoshimura A,. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387 (6636): 921-924. (Pubitemid 27289595)
70. Campbell JS, Prichard L, Schaper F, Schmitz J, Stephenson-Famy A, Rosenfeld ME, Argast GM, Heinrich PC, Fausto N,. Expression of suppressors of cytokine signaling during liver regeneration. J Clin Invest 2001; 107 (10): 1285-1292. (Pubitemid 32494545)
71. Dogusan Z, Hooghe-Peters EL, Berus D, Velkeniers B, Hooghe R,. Expression of SOCS genes in normal and leukemic human leukocytes stimulated by prolactin, growth hormone and cytokines. J Neuroimmunol 2000; 109 (1): 34-39.
72. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC,. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007; 67 (7): 764-773. (Pubitemid 46709445)
73. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z,. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001; 7 (9): 2941-2948. (Pubitemid 32911405)